www.bioscience.co.uk
Sales & Support: +44 (0)1223 316 855

Advanced HRD Biomarker Analysis

Mutations in the homologous recombination (HR) pathway lead to homologous recombination deficiency (HRD), which is associated with several types of cancers, including breast and ovarian cancer. HRD status can be measured by “cause” through mutations in the HRR pathway (e.g., BRCA1 and BRCA2) and by the “effect” of the presence of genomic scars at a given threshold or functional assay. HRD testing can identify 30% more PARPi-effective patients than BRCA testing alone (BRCA~20% vs. HRD~50%).

The AmoyDx HRD Focus Panel provides a focused and accurate test for HRD-related BRCA1/2 mutations and Genomic Scar Scores (GSS). The panel streamlines HRD testing and helps clinicians make more informed decisions about targeted therapy for patients with HRD-positive tumours.

Single-assay solution to detect all HRD parameters

Single assay for HRD status evaluation

Benefits of Amoy’s HRD focus panel

  • Comprehensive HRD detection – assesses both causes and effects of HRD
  • Enhances precision oncology – assists in determining patient eligibility for PARPi treatment
  • Advanced genomic instability assessment – utilises proprietary HANDLE technology and the Genomic Scar Score (GSS) algorithm for high-performance genomic instability detection
  • Seamless laboratory integration – compatible with the AmoyDx NGS Data Analysis System (ANDAS), providing automated and secure data analysis for streamlined workflows.
  • Fast and cost-effective – requires less than 1 hour of hands-on time, offering a dependable and efficient solution for evaluating PARPi-related biomarkers.

Applications of the HRD focus panel

  • Homologous recombination deficiency (HRD) status assessment
  • Predicting response to PARP inhibitors
  • Comprehensive genomic instability evaluation for precision oncology
  • Companion diagnostic for HRD-targeted therapies

Longer progression-free survival (PFS) with PARPi treatment for GSS-positive groups

Longer PFS with PARPi treatment in GSS-positive groups

The study highlights the promising value of GSS in identifying patients who may respond favorably to PARPi treatment.

Specifications

Target regions Whole coding regions and intron/exon boundaries of BRCA1 and BRCA2 genes and ~24,000 genome-wide SNPs
Alterations detected BRCA1/2 genes (SNVs/InDels) and Genomic Scar Score (GSS)
Sample type FFPE tissue
DNA input Optimal 100ng (minimum 50ng)
Data output per sample 4 Gb
Sequencing type PE150
Sequencer Illumina NextSeq 550Dx
TAT for library prep 5 hours (>1 hour hands-on time)
TAT from sample to report 3 days

Materials for download

AmoyDx® HRD Focus Panel brochure

AmoyDx® HRD Focus Panel user manual

Products

Note: product availability depends on country - see product detail page.

Details Cat number & supplier Size Price
HRD Focus Panel 8.06.0045 · Amoy Diagnostics
8.06.0045
Amoy Diagnostics
20 tests £16172.00
20 tests
view
HRD Focus Panel 8.06.0047 · Amoy Diagnostics
8.06.0047
Amoy Diagnostics
20 tests £16172.00
20 tests
view
HRD Complete Panel 8.06.0114 · Amoy Diagnostics
8.06.0114
Amoy Diagnostics
20 tests £16261.00
20 tests
view